Blockchain Registration Transaction Record

Candel Therapeutics' enLIGHTEN Discovery Platform Aims to Tackle Complexities of Tumor Microenvironments

Candel Therapeutics, Inc. leverages enLIGHTEN Discovery Platform for next-gen viral immunotherapy, presenting promising preclinical data at key industry conferences. Collaborations with University of Pennsylvania also in progress.

Candel Therapeutics' innovative approach to viral immunotherapy and the development of bespoke immunotherapies tailored for specific indications offer hope for addressing critical unmet needs in cancer treatment. The company's collaboration with the University of Pennsylvania also signals potential advancements in enhancing CAR T-cell therapies, providing a glimpse into the future of cancer immunotherapy research and treatment.